Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations.

ABSTRACT:

Introduction

Appropriate Use Recommendations (AURs) guide real-world use of lecanemab and donanemab in early symptomatic Alzheimer's disease (AD), but their applicability to Asian populations with diverse education backgrounds remains unclear.

Methods

Among 2726 participants who visited a Korean memory clinic, 1005 amyloid-positive participants with magnetic resonance imaging (MRI) and Clinical Dementia Rating data were included. Eligibility for lecanemab and donanemab was assessed using AUR criteria, including age, Mini-Mental State Examination (MMSE), brain MRI, apolipoprotein E genotype (for donanemab), and anticoagulant use, applying both raw and z-score-based MMSE thresholds.

Results

Among 1005 amyloid-positive participants, 24.6% were eligible for lecanemab and

SUBMITTER: Jeon SY 

PROVIDER: S-EPMC12611877 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature